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The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in ter-
tiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this
study was to evaluate the efficacy of integrated treatment of chronic HCV infection among
PWID.
Methods and findings
INTRO-HCV is a multicenter, randomized controlled clinical trial. Participants recruited from
opioid agonist therapy (OAT) and community care clinics in Norway over 2017 to 2019 were
randomly 1:1 assigned to the 2 treatment approaches. Integrated treatment was delivered
by multidisciplinary teams at opioid agonist treatment clinics or community care centers
(CCCs) for people with substance use disorders. This included on-site testing for HCV, liver
fibrosis assessment, counseling, treatment, and posttreatment follow-up. Standard treat-
ment was delivered in hospital outpatient clinics. Oral direct-acting antiviral (DAA) medica-
tions were administered in both arms. The study was not completely blinded. The primary
outcomes were time-to-treatment initiation and sustained virologic response (SVR), defined
as undetectable HCV RNA 12 weeks after treatment completion, analyzed with intention to
treat, and presented as hazard ratio (HR) and odds ratio (OR) with 95% confidence
intervals.
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Among 298 included participants, 150 were randomized to standard treatment, of which
116/150 (77%) initiated treatment, with 108/150 (72%) initiating within 1 year of referral.
Among those 148 randomized to integrated care, 145/148 (98%) initiated treatment, with
141/148 (95%) initiating within 1 year of referral. The HR for the time to initiating treatment in
the integrated arm was 2.2 (1.7 to 2.9) compared to standard treatment. SVR was confirmed
in 123 (85% of initiated/83% of all) for integrated treatment compared to 96 (83% of initiated/
64% of all) for the standard treatment (OR among treated: 1.5 [0.8 to 2.9], among all: 2.8
[1.6 to 4.8]). No severe adverse events were linked to the treatment.
Conclusions
Integrated treatment for HCV in PWID was superior to standard treatment in terms of time-
to-treatment initiation, and subsequently, more people achieved SVR. Among those who ini-
tiated treatment, the SVR rates were comparable. Scaling up of integrated treatment models




Why was this study done?
• People who inject drugs (PWID) suffer from a high burden of disease including chronic
hepatitis C virus (HCV) infection.
• Uptake of HCV treatment is often low in this population. Integrated care has been put
forward as a more beneficial approach by incorporating the treatment of comorbid con-
ditions into the treatment of substance use disorders, e.g., within specialized opioid ago-
nist therapy (OAT) clinics.
• To date, there is limited evidence comparing standard HCV treatment with integrated
treatment.
What did the researchers do and find?
• In this randomized controlled trial, a 19 percentage points absolute increase in sustained
virologic response (SVR) to HCV was seen among PWID who received integrated treat-
ment compared to those who received standard treatment.
• The treatment initiation rates were 21 percentage points higher among those who
received integrated treatment as compared to those who received standard treatment.
• The number needed to offer integrated treatment to achieve one additional SVR was 5.
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What do these findings mean?
Integrated treatment programs for PWID with HCV infection could substantially
improve overall treatment outcomes.
• Integrated treatment programs could be essential for HCV elimination and reducing
morbidity and mortality among PWID.
Introduction
The hepatitis C virus (HCV) epidemic has increased in many countries over the past few
decades. In the United States alone, it is estimated that around 34,000 people died in 2017 due
to severe hepatitis C complications such as cirrhosis and liver cancer [1]. HCV infection is
endemic among people who currently inject or formerly injected drugs (PWID) [2]. Globally,
43% of the HCV disease burden is attributable to drug injection, and in high-income coun-
tries, this fraction is 79% [3]. In recent years, highly efficacious direct-acting antiviral (DAA)
treatments for HCV infection have become available, prompting the World Health Organiza-
tion (WHO) to develop a global health strategy to eliminate HCV infection as a public health
threat by 2030 [4]. To achieve this goal, treatment models must address PWID [5].
Chronic HCV infection is a slowly progressive disease that can lead to liver cirrhosis and
subsequent complications, including hepatocellular carcinoma and liver failure [6,7]. In a
cohort of HCV-infected PWID, one-third developed advanced liver disease within 3 decades,
and liver disease and drug overdose became equally important causes of death among individ-
uals over 50 years [8,9]. Until recently, reports from opioid agonist therapy (OAT) clinics in
Norway indicated that about half of patients receiving OAT had chronic HCV infection [10].
Furthermore, the prevalence of ongoing injecting drug use and the subsequent transmission of
HCV is high in this population [11,12]. Thus, reaching PWID with HCV treatment is of criti-
cal importance for reducing both the HCV disease burden and HCV transmission.
Until 2014, HCV treatment was interferon based with moderate efficacy, considerable
adverse effects, and an accordingly low treatment uptake, particularly among PWID [13]. The
current availability of oral DAA has changed the HCV care paradigm and led to significant
therapeutic optimism [12]. However, HCV treatment coverage for PWID is far from universal
[14]. The World Hepatitis Summit in 2017 expressed concern over the lack of new healthcare
models with a patient-centered service delivery and integrated collaborative approaches [15].
To reduce this inequity, new models of care must be developed. Models focusing on interdisci-
plinarity, availability, and accessibility, with decentralized clinics and frequent follow-ups,
have been suggested [16–18]. Better evidence regarding these models of care for PWID is
needed [19–21].
In western Norway, OAT is provided with supervised and observed intake of medications
and frequent follow-ups by a multidisciplinary healthcare team that includes physicians,
nurses, social workers, peer counselors, and psychologists [22]. Multidisciplinary care and sup-
port at community care centers (CCCs) are offered to PWID not receiving OAT. The multidis-
ciplinary OAT clinics/CCC are well-suited delivery platforms to evaluate the efficacy of
integrated HCV care for PWID. To date, given the low coverage of HCV treatment in many
countries, surprisingly few trials with sufficient power have evaluated the efficacy of various
treatment approaches for HCV among PWID [20].
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This randomized controlled trial aims to compare the efficacy of integrated to standard
HCV treatment for PWID.
Methods
Study design and setting
The INTRO-HCV study is a multicenter, randomized controlled trial. The target population
was HCV-infected PWID eligible for treatment according to national guidelines. Patients with
substance use disorders were treated at 1 of the 8 OAT clinics or 2 CCC in Bergen and Sta-
vanger. For a more comprehensive description, a published study protocol is available [23].
OAT clinics located in each suburb served around 1,000 patients who were prescribed
buprenorphine or methadone and, less commonly, other opioids or additional benzodiaze-
pines or centrally acting stimulants [24]. This group of patients has a significant disease burden
and limited ability to utilize standard healthcare. In the area surrounding the included clinics,
around half of PWID had chronic HCV at the start of follow-up [25].
Participants
The study participants were comprised of PWID (1) receiving follow-up from OAT clinics/
CCC from an included clinic involving follow-up at least once weekly; (2) who were diagnosed
with detectable HCV RNA; (3) were eligible for treatment according to national HCV treat-
ment guidelines (see S1 Text); and (4) who provided written informed consent before inclu-
sion. Participants were excluded if they were currently receiving treatment for HCV, were
coinfected with human immunodeficiency virus (HIV), or had severe extrahepatic HCV mani-
festations (e.g., cryoglobulinemia or membrano-proliferative glomerulonephritis), chronic
kidney disease stage 4 to 5 (glomerular filtration rate<30 ml/min/1.73 m2), or decompensated
liver disease (Child–Pugh class B or C).
The study participants were PWID recruited from OAT clinics in Bergen (n = 901), Sta-
vanger (n = 130), and CCC in Bergen (n = 208). Of these, 136/1,237 (11%) did not provide
consent for participation. A total of 298 had untreated HCV with no exclusion criteria and
were valid for randomization (Fig 1).
Randomization and masking
Participants were randomized with a 1:1 ratio using blocks of 10 stratified by city and assigned
into integrated (n = 148) or standard care (n = 150) for inclusion in the trial. Complete blind-
ing was considered difficult and would have reduced external validity [26], although some
masking measures were taken [23]. In short, randomization was disclosed to clinical staff pro-
viding treatment and follow-up. Patients were informed of key elements in the delivery of the
respective intervention and follow-up they were randomized to, but not on information about
the treatment and follow-up alternatives in the other arm, nor the hypotheses for the study.
Interventions
Enrollment commenced in May 2017 and was completed in June 2019. For both arms, all the
primary stages of the study—including recruitment, information, obtaining written consents,
clinical interviews, completing the study surveys using appropriate instruments and blood
sampling, and liver fibrosis assessment for diagnostic purposes—were performed by research
nurses in close collaboration with the responsible multidisciplinary team at the OAT clinic/
CCC.
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Standard treatment
Participants eligible for standard treatment were referred for further assessment and treatment
at the collaborating medical outpatient clinic located in a central hospital. An appointment
was given and usually scheduled within a few weeks after the referral; the participants were
informed of this by mail. The diagnostic assessment often involved additional blood samples
and imaging before the initiation of DAA treatment. Once treatment was initiated, an elec-
tronic prescription was sent to a pharmacy during consultation. The DAA medications avail-
able were identical in the 2 trial arms and were prescribed in accordance with the national
treatment guidelines. Norway has a tender-based system, and, during the period, elbasvir/gra-
zoprevir, sofosbuvir/ledipasvir, or sofosbuvir/velpatasvir were the main combinations used
(see S1 Text). Standard treatment participants were generally offered follow-up consultations
every 4 weeks during treatment as well as a posttreatment assessment 12 weeks after comple-
tion. This typically involved a total of 4 to 5 consultation visits at the outpatient clinic.
For the standard treatment, patients needed to travel to the hospital clinic and pay for the
transport themselves, a distance that ranged from 1 to 25 km. Patients in the standard treat-
ment arm had standard follow-up in the OAT clinic for substance use disorders, and all other
types of care—apart from HCV care—were integrated into the OAT follow-up. The OAT site
staff encouraged participants to visit the infectious disease hospital clinics, but no further
Fig 1. Trial profile for the study. �Estimated numbers. HCV, hepatitis C infection; OAT, opioid agonist therapy; PWID,
people who inject drugs.
https://doi.org/10.1371/journal.pmed.1003653.g001
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extensive follow-up was given. There was a risk that scheduled appointments may overlap with
other activities such as other healthcare, since arrangements were not coordinated. Blood sam-
ples were routinely taken every 4 weeks during treatment.
Integrated treatment
Integrated treatment was delivered at OAT clinics or CCC by multidisciplinary teams in both
of the settings. OAT clinics differed from CCC by offering OAT medications in addition to
psychosocial approaches. Psychosocial approaches were also provided at CCC. The multidisci-
plinary team at the OAT clinics were equipped with specialists in addiction medicine who
were responsible for the OAT and other medical follow-ups and also psychologists providing
mental health treatment. In both settings, nurses and social workers in cooperation with peer
counselors provided most of the daily follow-ups of the patients. All these professionals were
existing clinical staff who closely worked together with the research nurses in management of
the interventions and evaluations during the study period. For those found to be eligible for
HCV treatment, DAA medications were administered by a nurse at the OAT clinic/CCC after
prescription from a specialist physician. All HCV treatment and scheduled follow-up during
treatment were given in parallel with the delivery of OAT medications and other care in line
with the study protocol (usually several times per week). Dispensation was therefore adapted
to the level of functioning for each individual patient. For the most severely ill patients with
the lowest level of daily functioning and high intake of multiple drugs, OAT medications and
HCV treatment were normally dispensed daily in the OAT clinic, and intake was observed by
a nurse. For patients with a high level of functioning, dispensation could be done, for example,
on a weekly basis.
Frequency of blood sampling during integrated treatment was mainly taken according to
clinical indication (e.g., suspected adverse effects or complications). Less frequent blood sam-
pling may reduce discomfort compared to standard treatment, where blood samples are usu-
ally taken every 4 weeks during treatment. To assess treatment efficacy, a new blood sample
was drawn by a research nurse 12 weeks after treatment completion.
Outcomes and assessments
The primary outcome measures were as follows:
• Treatment uptake, defined as initiation of DAA among participants eligible for HCV treat-
ment, was assessed with time-to-event analyses and initiation status. In the time-to-event
analyses, the first time point was when participants were diagnosed with chronic HCV infec-
tion, and the second time point was when treatment was initiated. We also present stratified
analyses on patient-related delay (including time since missed appointments) and system-
related delay (including delay until received appointment).
• Sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after com-
pletion of treatment with DAA. This was assessed as a dichotomous SVR status. The viro-
logic blood samples in Bergen were analyzed at the Department for Microbiology at
Haukeland University Hospital (accredited by ISO standard 15189) after being centrifuged
at each study clinic before transfer. Similar procedures were used in Stavanger.
Transient elastography was used in the screening of cirrhosis (median of 10 measurements
>12.5 kPa on an empty stomach using FibroScan 430 mini) [27,28], and hepatic encephalopa-
thy was assessed according to the West Haven criteria [29]. For details on clinical and demo-
graphic data, see Table 1.
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The blood samples for the primary outcome measures were collected at the OAT clinics/
CCC for participants randomized into integrated care and at the hospital outpatient clinic for
the participants randomized into standard treatment. However, for participants who did not
come to the assessment at the hospital clinic 12 weeks after treatment, blood samples were col-
lected at the OAT clinics/CCC.
Statistical analyses
A sample size was calculated with the following assumptions: 90% power with a two-sided
alpha (α) error of 5%, 50%/80% rates of SVR among all randomized to standard/integrated
Table 1. Demographic and clinical characteristics at baseline for participants in standard and integrated treat-
ment groups presented with numbers in each group with percentages or median (25%–75%) for age and body
mass index.
Standard treatment Integrated treatment
n (%) 150 (50%) 148 (50%)
Age 42 (34–50) 44 (36–52)
Education: <10 years 82 (57%) 77 (52%)
Education: 10–12 years 47 (33%) 57 (39%)
Education: >12 years 14 (10%) 14 (9%)
Male 121 (81%) 108 (73%)
Homelessness
Social security benefits as income








Buprenorphine based 69 (46%) 72 (49%)
Methadone 56 (37%) 57 (39%)
Non-OAT (receiving CCC) 23 (15%) 18 (12%)
Injecting drug use (ever)
Injecting drug use (last 6 months)
Injecting drug use (last 30 days)









Substance use last 30 days
Illicit opioids 38 (29) 33 (22)
Amphetamines or cocaine 63 (47) 68 (46)
Benzodiazepines 78 (59) 86 (59)
Cannabinoids 88 (66) 111 (76)
Tobacco 123 (92) 138 (94)
Alcohol 78 (59) 81 (55)
Body mass index (kg/m2) 24 (22–28) 24 (22–28)
Genotype
Genotype 1 50 (34%) 51 (35%)
Genotype 2 6 (4%) 2 (1%)
Genotype 3 89 (61%) 94 (64%)
Other genotypes 2 (1%) 0 (0%)






Missing values are excluded from percentages.
�
Probable fibrosis (not cirrhosis): elastography measure of 7.0–12.5 kPa.
��Probable cirrhosis: elastography measure of >12.5 kPa.
CCC, community care center; OAT, opioid agonist therapy.
https://doi.org/10.1371/journal.pmed.1003653.t001
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treatment, up to 33% lost to follow-up, and equal proportions between the groups, with 87
required per group and 174 in total. We also calculated sample size requirements to detect a
1.5 hazard ratio (HR) difference in time to treatment initiation between the arms (post hoc),
with 90% power and an alpha of 5%, yielding 134 required per group and 268 in total. Due to
logistical reasons such as study recruitment being very rapid during the last month, the num-
ber of participants exceeded the precalculated necessary sample size.
Analysis was conducted in Stata SE16 and followed the CONSORT guidelines [30]. We
present intention-to-treat (ITT) analyses by including all participants based on randomization,
where those lost to follow-up are assumed to persist as HCV infected. Per protocol analyses
are also presented, where those with protocol violations are excluded. For SVR per protocol
analyses, also those without valid HCV PCR measures 12 weeks after completed treatment are
excluded. All tests are two-sided. Descriptive results and efficacy estimates are presented with
95% confidence intervals. The statistical significance is set at p< 0.05. Categorical variables
are summarized as percentages and continuous variables as medians with interquartile ranges
(IQRs). The time-to-event analyses are presented with Kaplan–Meier plots for both treatment
arms and Cox regression using randomization arm as independent variable and time-to-treat-
ment initiation as dependent variables, presented as HRs with 95% confidence intervals. For
binary outcomes of SVR, logistic regression analyses are presented as odds ratios (ORs) with
95% confidence intervals. The proportional hazards assumption was also checked using
Schoenfeld residuals. The ITT analyses did not violate the assumption significantly, but some
violation was seen with the per protocol analyses (S1 Table). Thus, sensitivity analyses with
split time for treatment initiation was conducted with time splits at 2, 6, and 12 months. To
account for potential within clinic variation, we also did sensitivity analyses adjusting for clus-
tering in the regression models. Additional post hoc subgroups analyses stratified for gender,
geographic location, age group, living condition, likely fibrosis and cirrhosis, and injecting
drug behavior during the last 6 months are presented, as are analyses taking potential cluster-
ing effects into consideration. Tests for the interactions in the models are presented with p-val-
ues for the interaction between the subgroup and arm when including the arm and each
subgroup separately. We also present subgroup Kaplan–Meier plots for the dominant geno-
types. All severe adverse effects are reported.
Ethics
The study has been approved by regional ethical committee (no. 2017/51/REK Vest). The trial
was conducted in accordance with the Declaration of Helsinki and other international conven-
tions and with Good Clinical Practice and Good Laboratory Practice standards [31,32]. Writ-
ten informed consent was obtained from each participant.
Results
The characteristics of study participants were similar in the 2 arms with a median age of 44
years (IQR 36 to 52) in the integrated care arm and 42 years (IQR 34 to 50) in standard treat-
ment arm (Table 1). The majority for both arms were male (77%, 229/298), had received
buprenorphine-based OAT (47%, 141/298) or methadone (38%, 113/298), had injected drugs
within the last 6 months (60%, 168/280), and received supervised and observed treatment with
a median of 5 times per week (IQR 3 to 6) in an OAT outpatient clinic. Homelessness, defined
as not having a rented or owned home nor living together with family, was reported among
14% (41/298) of study participants. All participants had a history of injecting drug use. During
the last month, 88% (261/298) had smoked tobacco and 67% (199/298) cannabinoids, 44%
(131/298) used stimulants such as amphetamine, methamphetamine, or cocaine, 55% (164/
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298) had used benzodiazepines, 53% (159/298) had used alcohol, and 24% (71/298) used illicit
opioids such as heroin. For 23% (62/270) participants, the elastography indicated fibrosis but
not cirrhosis, and for 13% (35/270), cirrhosis was likely. Almost all had HCV infection with
genotype 1 or 3 (97%, 284/294).
In the integrated care arm, 98% (145/148) initiated treatment, and 94% (139/148) started
within 1 year of referral (Table 2). Among people randomized to standard treatment, 77%
(116/150) initiated treatment, and 72% (108/150) started within 1 year of referral. Median
time to HCV treatment initiation was 71 days (IQR 39 to 112) in the integrated care arm, of
which system delay (until receiving time for appointment) contributed to 51 days (IQR 23 to
104). In contrast, for the standard treatment arm, the median time to HCV treatment initia-
tion was 120 days (IQR 47 to 248), with a system delay of 81 days (IQR 32 to 192; Fig 2). The
HR for the time to initiating treatment in the integrated arm was 2.2 (1.7 to 2.9) compared to
standard treatment. For the binary treatment initiation outcome, logistic regression indicated
an OR of 6.8 (3.1 to 15) for initiating treatment within 1 year in the integrated arm compared
to the standard arm. For per protocol analyses excluding participants with protocol violations,
the HR for the time to initiating treatment was 1.9 (1.5 to 2.5) for integrated compared to stan-
dard treatment (S1 Fig).
Among all participants who were randomized, the ITT analyses showed that the SVR was
achieved in 123 (83%) in the integrated treatment arm and 96 (64%) in the standard treatment
arm. For patients who initiated treatment, SVR was achieved in 85% receiving integrated treat-
ment compared to 83% receiving standard treatment. In the per protocol analyses when
excluding persons with protocol violations or no valid posttreatment PCR test, SVR was con-
firmed among 94% (123/130) receiving integrated treatment and 88% (84/96) receiving stan-
dard treatment, OR 2.5 (0.9 to 6.6).
Subgroup analyses of the SVR among those who initiated treatment (Fig 3) indicated that
the intervention increased SVR most among participants above 50 years of age but also tended
to increase SVR more among female participants and those with injecting drug use not receiv-
ing OAT. Most groups had superior outcomes from integrated treatment compared to stan-
dard treatment when comparing SVR among all who were randomized (Fig 4 and S2 Fig).
For the sensitivity analyses with split time (S1 Table), the HR for time to treatment initia-
tion comparing the integrated arm with the standard arm in the time range 0 to 2 months was
Table 2. Primary end point analysis presented for treatment initiation with both ITT and PP analyses.
Outcome Events, No. (%) Absolute increase (%, 95% CI) Cox/glm.reg. HR/OR Cox/glm.reg. (clustering)
Integrated Standard
Treatment initiation, ITT 145 (98) 116 (77) 21 (14–28) 2.2 (1.7–2.9) 2.2 (1.6–3.0)
Treatment initiation, PP 145 (98) 107 (82) 16 (9–22) 1.9 (1.5–2.5) 1.9 (1.5–2.5)
HCV SVR (initiated), ITT 123 (85) 91 (78) 6 (−3–16) 1.5 (0.8–2.9) 1.5 (0.9–2.6)
HCV SVR (init. + test), PP 123 (94) 84 (88) 7 (0–14) 2.5 (0.9–6.6) 2.5 (1.2–5.2)
HCV SVR (all), ITT 123 (83) 96 (64) 19 (9–29) 2.8 (1.6–4.8) 2.8 (1.7–4.5)
HCV SVR (all + test), PP 123 (93) 84 (73) 20 (11–29) 5.0 (2.3–11) 5.0 (2.3–11)
SAE (assumed linked) 0 (0) 0 (0)
SVRs are presented for those who initiated treatment (marked “initiated”) and for all who were randomized (marked “all”). No related SAEs were observed. Both
number of events, absolute increase, and relative changes assessed with HR for treatment initiation (analyzed with Cox regression) and OR for SVR (analyzed with GLM
regression).
GLM, generalized linear model; HCV, hepatitis C virus; HR, hazard ratio; ITT, intention-to-treat; OR, odds ratio; PP, per protocol; SAE, severe adverse event; SVR,
sustained virologic response.
https://doi.org/10.1371/journal.pmed.1003653.t002
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1.4 (1.0 to 2.1), between 2 and 6 months was 3.5 (2.4 to 5.1), and between 6 and 12 months was
2.2 (1.0 to 4.8). There were no clear differences in time-to-treatment initiation between the
genotypes (S3 and S4 Figs). Out of 101 persons with genotype 1, 55% were treated with elbas-
vir/grazoprevir and 40% with sofosbuvir/ledipasvir. Among 183 persons with genotype 3, 93%
were treated with sofosbuvir/velpatasvir. Except for the sofosbuvir/ledipasvir combination that
was usually given for 8 weeks, other treatments were generally administered for 12 weeks.
Three deaths were recorded among the trial participants, 2 receiving the integrated treat-
ment and 1 receiving standard treatment. These deaths were linked to overdose, suicide, and
murder, with none being associated with the HCV treatment. In addition, there was a near
fatal suicide attempt concerning an individual undergoing standard treatment, also considered
unlikely to be linked to the treatment. No other serious adverse events were recorded. One-
tenth of the participants had noteworthy side effects such as fatigue, nausea, headache, and
stomach pain during the treatment. Approximately half of these ceased the treatment due to
the side effects. For a few participants in the standard treatment, there was an issue with medi-
cations being lost due to theft.
Discussion
This study provides strong evidence supporting the effect of integrating HCV treatment among
PWID into OAT/CCC. The trial showed a substantial increase in SVR among those eligible for
treatment, with a 19 percentage points absolute difference seen in favor of the integrated treat-
ment model compared to standard treatment. For treatment initiation, a 21 percentage points
absolute difference was seen in favor of the integrated treatment model and a reduction by half
in the time to treatment initiation. No associated serious adverse events were recorded.
Fig 2. Time to hepatitis C treatment initiation presented with Kaplan–Meier plot. Red line/area indicates
proportion of participants in integrated arm initiation treatment with confidence intervals. Blue dashed line/area
indicates proportion of participants in standard treatment arm initiation treatment.
https://doi.org/10.1371/journal.pmed.1003653.g002
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Integrated treatment models have shown they can provide an excellent opportunity to
improve treatment initiation/uptake to HCV treatment, and so could be essential to the aim of
providing universal coverage of HCV among marginalized populations with substance use dis-
orders [15]. Representing a model of care suited to engage OAT patients in HCV care, this
study should inform HCV elimination efforts internationally and replace the current referral-
based standard treatment for this patient group.
A previous three-arm randomized controlled trial (PREVAIL) of 3 models of care for the
treatment of HCV among PWID showed that directly observed treatment was more effective
in improving adherence to HCV treatment than self-administered individual treatment [33].
However, this study from the Bronx in New York City was conducted during a transition time
when interferon was still in use. There was no comparison with the current standard treat-
ment, and it was not powered to assess differences in SVR between the treatment models. Our
study is among the first trials in the DAA era to examine the efficacy of integrated treatment
compared to referral-based standard treatment. HCV treatment has become increasingly sim-
ple and effective to administer, except for a small minority of patients with severe liver disease,
and so tertiary healthcare is less necessary. We hypothesize a significant effect of integrated
treatment and care models in the management and follow-up of a range of comorbid physical
and mental conditions among people currently injecting substances. These populations might
be more vulnerable and have more difficulties in daily functioning, making it challenging to
utilize usual healthcare services. There is an urgent need to assimilate the health system and
care services to improve access to highly efficacious HCV treatment for the most vulnerable
population groups.
Fig 3. Subgroup analyses for binomial logit regression of SVR of hepatitis C for those who initiated treatment
comparing the integrated arm with the standard arm (post hoc ITT analyses). Subgroup effects are presented for
gender, the type of treatment center, age group, living condition, injecting drug use behavior the last 6 months, fibrosis
and cirrhosis, and overall effects (without and with cluster adjustment)��. �Non-OAT: patients who did not receive
OAT. ��Interaction tests: sex: p = 0.069, site: p = 0.737, OAT/non-OAT: p = 0.095, age: p = 0.023, living condition:
p = 0.367, injecting drugs: p = 0.309, fibrosis/cirrhosis: p = 0.605. ITT, intention-to-treat; OAT, opioid agonist therapy;
OR, odds ratio; SVR, sustained virologic response.
https://doi.org/10.1371/journal.pmed.1003653.g003
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In our study, only 3 out of 4 patients referred to standard treatment initiated treatment.
This is higher than findings from other, such as among PWID in Melbourne, Australia,
where only 1 in 3 of those referred to hospital actually commenced HCV treatment [34]. It is
worth noting that participants in the standard treatment arm in our trial received an inte-
grated assessment beyond what was common in many similar settings in Norway and proba-
bly also in other countries. The difference between our trial and the study from Australia
might be related to our standard arms receiving these integrated assessments including blood
samples for genotyping as well as elastography, which reduced the number of visits in stan-
dard treatment before treatment initiation. Among those who initiated treatment across in
our trial and had valid SVR tests, 94% in the integrated arm and 88% in the standard arm
achieved SVR, which is comparable to a trial on DAA medications where 92% achieved SVR
[35]. Studies on integrated diagnostics have already shown improved case findings [36].
Thus, the difference between standard treatment without active case finding procedures and
our integrated assessment and treatment model may even have been larger than the differ-
ences seen in our trial.
Our trial involves several strengths and limitations. The treatment evaluation (assessment
of outcomes) and treatment follow-up were undertaken by independent teams. The study is
individually randomized with balanced groups, minimizing the potential for confounding.
The study size was also more than sufficient to answer the primary objectives with high preci-
sion. Moreover, the study was also funded by public sources minimizing potential conflicts of
Fig 4. Subgroup analyses for binomial logit regression of SVR of hepatitis C for all who were randomized
comparing the integrated arm with the standard arm (post hoc ITT analyses). Subgroup effects are presented for
gender, the type of treatment center, age group, living condition, injecting drug use behavior the last 6 months, fibrosis
and cirrhosis, and overall effects (without and with cluster adjustment)��. �Non-OAT: patients who did not receive
OAT. ��Interaction tests: sex: p = 0.231, site: p = 0.358, OAT/non-OAT: p = 0.237, age: p = 0.041, living condition:
p = 0.928, injecting drugs: p = 0.972, fibrosis/cirrhosis: p = 0.382. ITT, intention-to-treat; OAT, opioid agonist therapy;
OR, odds ratio; SVR, sustained virologic response.
https://doi.org/10.1371/journal.pmed.1003653.g004
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interest. In terms of safety, the frequent follow-up of the participants likely improved detection
of potential adverse effects of applied medications. The population of PWID includes a large
proportion that is struggling with standard treatment pathways due to their substance use dis-
orders. For individuals with higher levels of functioning and less need for regular treatment
follow-up, the need for treatment integration might be less important and have less beneficial
effect.
It could be argued that integrated care provides added benefits in contrast to hospital care,
related to culture, attitudes, and philosophy of care in the direction of anti-stigma, psychologi-
cal safety, and relational continuity. Integrated care may also provide additional support,
engagement, and knowledge of substance use via specialized multidisciplinary teams. A limita-
tion of the present study is that the benefits of the separate elements of the integrated care
model cannot be differentiated. Still, we argue that the benefits of integrated care are related to
a combination of these benefits in addition to ease of access. This is a first step in developing a
better care model, with the next step being to disentangle the effects of the different compo-
nents of the integrated care model.
It should be noted that OAT in the region of study was performed and administered at
centralized clinics. In regions where OAT is provided by primary care, models of HCV care
might need local adaptations. In the OAT population, 11% had received HCV treatment
prior to the trial, and a similar percentage did not provide consent to study participation.
Thus, some participants that may be less hard to reach were treated outside this trial. As 5
times as many of the target population were treated inside the trial as before study initiation,
this is unlikely to cause a substantial selection bias. When taking potential clustering within
the 10 treatment centers into consideration, only minor changes in the confidence intervals
were observed. We adhered to the commonly used standard of SVR 12 weeks after treatment
completion. An earlier outcome measure might have reduced loss to follow-up and
improved our evaluation of who had been successfully treated. However, most of the loss to
follow-up before SVR testing was among persons not initiating treatment, and so not achiev-
ing SVR is likely to be a robust assumption. In the time prior to the national guidelines that
allowed for immediate HCV treatment, there was some delay in treatment initiation for sev-
eral participants in both arms of the study. This might have negatively impacted their treat-
ment outcomes, although it was balanced between the arms. For the trial, complete blinding
was not possible. However, due to the assessment of a biological primary outcome such as
HCV SVR, we assume that information bias is unlikely to have substantially distorted our
findings. One can view trials as a continuity from efficacy trials optimizing internal validity
through homogeneous population to effectiveness trials optimizing external validity with a
more heterogeneous population. This trial is more toward the effectiveness side of the
spectrum.
An important question for trials of different treatment models is how these models can be
successfully sustained outside the trial settings. As existing clinic staff were used to deliver the
intervention within existing clinical frameworks and settings, the intervention is considered
sustainable.
In conclusion, integrating hepatitis C treatment into multidisciplinary OAT clinics and
CCCs for PWID was found to be superior to standard treatment at hospital, both in terms of
time-to-treatment initiation and subsequently achieving SVR among more patients. Among
those who initiated treatment, the rates of SVR were comparable. No differences in severe
adverse effects were shown between the arms. Scaling up of integrated treatment models could
be an essential tool for the elimination of hepatitis C infection among people with substance
use disorders.
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